Biovie Stock : BIVI

Earnings Reports

BioVie Corporate Presentation

Please download our corporate presentation for more specific information about how we intend to address the unmet medical need of acites due to liver cirrhosis


Please download our poster presentations at the AASLD and EASL liver meetings.

The Pharmacokinetics of Terlipressin Administered as a Continuous Infusion in Six Cirrhotic Patients with Refractory Ascites

U.S. Hospitalization Characteristics of Cirrhotic Patients with Ascites Receiving Paracentesis

Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Activity of Terlipressin Delivered by Continuous Intravenous Infusion in Patients with Cirrhosis and Refractory Ascites: A Phase 2a Open Label Trial

Recent Press

Forward Looking Statements

This website contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties and assumptions that could cause BioVie’s actual results and experience to differ materially from anticipated results and expectations expressed in these forward-looking statements. BioVie has in some cases identified forward-looking statements by using words such as “anticipates,” “believes,” “hopes,” “estimates,” “looks,” “expects,” “plans,” “intends,” “goal,” “potential,” “may,” “suggest,” and similar expressions. Among other factors that could cause actual results to differ materially from those expressed in forward-looking statements are BioVie’s need for, and the availability of, substantial capital in the future to fund its operations and research and development. The fact is that BioVie’s compounds may not successfully complete pre-clinical or clinical testing, or be granted regulatory approval to be sold and marketed in the United States or elsewhere. A more complete description of these risk factors is included in BioVie’s filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. BioVie undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.